Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5 microg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20 microg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophylline SR in Severe COPD Patients.

Trial Profile

Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5 microg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20 microg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophylline SR in Severe COPD Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Ipratropium bromide; Theophylline
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms SECURE 2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Sep 2011 Additional trial location (China) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top